PaxMedica, Inc. (PXMD)

Market Cap	5.93M
Revenue (ttm)	n/a
Net Income (ttm)	-18.29M
Shares Out	7.41M
EPS (ttm)	-11.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,998,388
Open	0.690
Previous Close	0.660
Day's Range	0.602 - 0.889
52-Week Range	0.372 - 38.930
Beta	n/a
Analysts	Strong Buy
Price Target	3.00 (+275.05%)
Earnings Date	May 13, 2024

About PXMD

PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is dev...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 2022
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: PXMD

Analyst Forecast

According to one analyst, the rating for PXMD stock is "Strong Buy" and the 12-month stock price forecast is $3.0.

Price Target

$3.0

(275.05% upside)

Analyst Consensus: Strong Buy